Dynamic Technology Lab Private Ltd Invests $765,000 in Amphastar Pharmaceuticals, Inc. $AMPH

Dynamic Technology Lab Private Ltd bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 33,300 shares of the company’s stock, valued at approximately $765,000.

Several other hedge funds and other institutional investors also recently modified their holdings of AMPH. Creative Planning lifted its holdings in Amphastar Pharmaceuticals by 111.8% in the second quarter. Creative Planning now owns 42,620 shares of the company’s stock worth $979,000 after buying an additional 22,493 shares during the period. SG Americas Securities LLC bought a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $561,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Amphastar Pharmaceuticals by 5.2% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company’s stock worth $217,000 after acquiring an additional 465 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock valued at $22,348,000 after purchasing an additional 18,161 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Amphastar Pharmaceuticals by 35.5% during the second quarter. PNC Financial Services Group Inc. now owns 6,483 shares of the company’s stock valued at $149,000 after purchasing an additional 1,700 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Bank of America increased their price objective on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 26th. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, November 17th. Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Finally, Needham & Company LLC decreased their target price on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $31.20.

Amphastar Pharmaceuticals Stock Up 2.6%

NASDAQ:AMPH opened at $26.01 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. The firm has a market cap of $1.20 billion, a P/E ratio of 9.74 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $46.43. The firm has a 50-day simple moving average of $25.61 and a two-hundred day simple moving average of $25.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to the consensus estimate of $186.90 million. Amphastar Pharmaceuticals had a net margin of 18.64% and a return on equity of 20.76%. Analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 16,679 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total value of $441,826.71. Following the completion of the sale, the director owned 75,531 shares of the company’s stock, valued at approximately $2,000,816.19. This trade represents a 18.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 17,679 shares of company stock worth $468,062. Company insiders own 27.50% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.